Edition:
United Kingdom

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

31.25USD
8:59pm GMT
Change (% chg)

$1.10 (+3.65%)
Prev Close
$30.15
Open
$29.70
Day's High
$31.92
Day's Low
$29.70
Volume
245,416
Avg. Vol
221,362
52-wk High
$58.80
52-wk Low
$29.38

Select another date:

Thu, Feb 15 2018

BRIEF-Pacira Says FDA ‍committee ‍Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia​

* PACIRA PHARMACEUTICALS STATEMENT ON FDA ADVISORY COMMITTEE FOR EXPAREL® FOR USE AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA

BRIEF-Pacira Pharmaceuticals Says FDA Advisory Committee To Review SNDA For Exparel

* PACIRA PHARMACEUTICALS STOCK TRADING HALTED; FDA ADVISORY COMMITTEE TO REVIEW SNDA FOR EXPAREL® AS A NERVE BLOCK FOR REGIONAL ANALGESIA Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel

* PACIRA PHARMACEUTICALS INC - FDA POSTS BRIEFING DOCUMENTS FOR ADVISORY MEETING REVIEWING SNDA FOR EXPAREL AS A NERVE BLOCK FOR REGIONAL ANALGESIA

BRIEF-Wellstar And Pacira To Minimize Opioid Use Across Surgical Procedures

* WELLSTAR HEALTH SYSTEM AND PACIRA PHARMACEUTICALS ANNOUNCE PARTNERSHIP TO MINIMIZE OPIOID USE AND STANDARDIZE OUTCOMES ACROSS SURGICAL PROCEDURES Source text for Eikon: Further company coverage:

BRIEF-Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million

* PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia

BRIEF-Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11

* Pacira Pharmaceuticals Inc reports third quarter 2017 financial results

BRIEF-Pacira Pharma to invest up to $25 million in Tela Bio

* Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​

BRIEF-Pacira Pharmaceuticals announces FDA acceptance of SNDA

* Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia

BRIEF-‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​

* ‍Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing ​ Source text: (http://bit.ly/2io69IV) Further company coverage:

Select another date: